Cargando…
Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
BACKGROUND: Subcutaneous immunoglobulin (SCIG) is increasingly utilized in primary immunodeficiency (PI). Understanding factors associated with treatment experience and satisfaction can optimize patient outcomes. We analyzed Immune Deficiency Foundation (IDF) survey data to evaluate patient-reported...
Autores principales: | Mallick, R., Henderson, T., Lahue, B. J., Kafal, A., Bassett, P., Scalchunes, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418302/ https://www.ncbi.nlm.nih.gov/pubmed/32778048 http://dx.doi.org/10.1186/s12865-020-00371-y |
Ejemplares similares
-
Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes
por: Mallick, Rajiv, et al.
Publicado: (2022) -
Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013) -
Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
por: Walter, Graham, et al.
Publicado: (2020) -
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2016) -
Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
por: Gupta, Sudhir, et al.
Publicado: (2023)